Blocking TGF-β Receptor in Liver Cells Revives Exhausted T Cells Against Metastasis
Mouse study finds that silencing TβRI in hepatocytes curbs liver metastases and boosts αPD-1 therapy by reviving stem-like CD8+ T cells.
Résumé
Liver metastases respond poorly to immunotherapy. Researchers examined 36 colorectal liver metastasis (CRLM) specimens and found that 75% had high TGF-β receptor I (TβRI) in liver tissue bordering the tumor, mainly in hepatocytes. High expression tracked with shorter survival. In mice lacking TβRI only in hepatocytes, liver metastases from colorectal, pancreatic and melanoma cells grew less in the later stages, though early tumor seeding was unchanged. The authors report that blocking hepatocyte TGF-β signaling lowers Galectin-9 secretion and shifts CD8+ T cells away from terminal exhaustion toward stem-like and effector states. This worked independently of macrophages and CD4+ T cells. A lipid nanoparticle carrying the TβRI inhibitor Galunisertib combined with αPD-1 further suppressed metastases in mice. The work is preclinical, but it points to hepatocytes as a possible immunotherapy target.
Résumé détaillé
Why this matters: The liver is the most common site of distant metastasis, and patients with liver metastases benefit less from immune checkpoint blockade than those with metastases elsewhere. The liver's naturally tolerant immune environment is thought to be a major reason. Stem-like exhausted CD8+ T cells (PD1+TCF1+Ly108+) are the reservoir that sustains durable antitumor responses. Their loss to terminally exhausted states limits therapy. TGF-β is a known immunosuppressive driver, but the role of TGF-β signaling in hepatocytes, the dominant liver cell type, had been poorly defined.
What was studied: The team first stained 36 microsatellite-stable colorectal liver metastasis specimens from patients who had received no neoadjuvant therapy. They then built mice with hepatocyte-specific TβRI deletion (TβRI-flox/flox Alb-Cre, 'TβRI-hKO') and compared them with wild-type littermates. They modeled liver metastasis with MC38 colorectal cancer (immunotherapy-sensitive) and B16F10 melanoma and PAN02 pancreatic cancer (immunotherapy-resistant). Immune profiling tracked CD8+ T cell differentiation from effector-like to exhausted states.
Key results: High TβRI appeared in the peri-metastatic liver in 75% of patient cases (27/36), mostly in hepatocytes, with some in stellate cells and little in macrophages. About 70% of TβRI-high cases also showed phosphorylated Smad2 in those hepatocytes, indicating active signaling. Patients with TβRI-high peri-metastatic tissue had shorter overall survival. In mice, tumor colonization at day 7 was similar between genotypes, but TβRI-hKO mice had lower metastatic burden at later time points in all three models. Total numbers of CD4+/CD8+ T cells, MDSCs, dendritic cells and NK/NKT cells were preserved, while tumor-associated macrophages were reduced. TβRI-hKO suppressed terminal Tex differentiation (PD1hi with TIM3, TIGIT and LAG3), although the increase in PD1-intermediate progenitor cells was modest (about 10%) and seen only at one time point in MC38. Per the abstract, hepatocytic TβRI blockade lowers Galectin-9 secretion, reprogramming CD8+ T cells toward stem-like and effector states, independent of macrophages and CD4+ T cells. Choline-modified lipid nanoparticles delivering Galunisertib combined with αPD-1 produced Ly108+CX3CR1+ responsive T cells and suppressed liver metastases.
Implications and caveats: Hepatocyte TGF-β signaling may be a targetable checkpoint in liver metastasis, and liver-directed delivery could make TGF-β inhibition more tolerable alongside checkpoint therapy. The evidence is mainly from mouse models. The human data are a small, single-center correlative cohort, and genetic deletion differs from pharmacologic inhibition. The full text provided to us was truncated, so the Galectin-9 mechanism and nanoparticle therapy data are summarized from the abstract only.
Principales conclusions
- High TβRI in peri-metastatic liver tissue occurred in 75% (27/36) of CRLM cases and was associated with shorter overall survival.
- Hepatocyte-specific TβRI knockout reduced late-stage liver metastatic burden in MC38, PAN02 and B16F10 models, without affecting day-7 colonization.
- Hepatocytic TβRI blockade suppressed Galectin-9 secretion and shifted CD8+ T cells from terminal exhaustion toward stem-like and effector states.
- The effect was independent of macrophages and CD4+ T cells, per the authors, even though tumor-associated macrophages decreased in knockout mice.
- Galunisertib-loaded choline-modified lipid nanoparticles synergized with αPD-1, generating Ly108+CX3CR1+ T cells and suppressing liver metastases in mice.
Méthodologie
Immunohistochemistry and multiplex IHC were performed on 36 MSS colorectal liver metastasis specimens, with multivariate Cox survival analysis. Hepatocyte-specific TβRI knockout mice (Alb-Cre) were compared with wild-type controls in intrasplenic-style liver metastasis models using MC38, PAN02 and B16F10 cells (n=5-6 mice/group), with flow cytometric T cell profiling. Therapeutic testing used Galunisertib-loaded lipid nanoparticles with αPD-1.
Limites de l'étude
Functional evidence comes from mouse models using genetic knockout, which may not reflect the effects of pharmacologic inhibition in patients. The human cohort is small (n=36), single-center and correlative. The text available was truncated, so the Galectin-9 mechanism and nanoparticle results are based on the abstract, and the progenitor T cell effect was modest and inconsistent across models.
Ce résumé vous a plu ?
Recevez les dernières recherches sur la longévité dans votre boîte de réception chaque semaine.
Saisissez votre e-mail pour vous abonner :